Clinical trial Recruiting at 1 site Observational Ages 18 to 50 Women only

Epigenetic markers linked to PMDD across the menstrual cycle

Official title: Identification and Validation of Epigenetic Biomarkers of PMDD

Run by Johns Hopkins University · NCT06771583 · Data updated 2026-11-12

This study tests whether blood epigenetic markers can tell apart women with PMDD from women without PMDD at different points in the menstrual cycle.

Quick facts

Study typeObservational
Ages18 Years to 50 Years
SexWomen only
Enrollment500 (estimated)
SponsorJohns Hopkins University
Academic / other
Locations1 site (Baltimore, Maryland)
StatusRecruiting
StartedSeptember 12, 2025
Main results expectedFebruary 15, 2030
Study endsFebruary 15, 2031
Registry record updatedMay 7, 2026
Trial IDNCT06771583 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women aged 18–50 with regular menstrual cycles who either have PMDD or do not have PMDD and who meet the study's medication and health criteria.

Probably not a fit

Women using steroid hormones or hormonal contraceptives, those with recent psychiatric medication or substance use disorders, recent pregnancy, uncontrolled endocrine disease, very high BMI, or recent major psychiatric illness are excluded and unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects blood samples and mood ratings from women with PMDD and from control women across the follicular and luteal phases of their menstrual cycles. Investigators will measure DNA methylation biomarkers previously linked to postpartum depression and use a repeated-measures approach to see if these markers vary by diagnosis and cycle phase. A secondary aim compares biomarkers between PMDD participants who have responded to SSRI treatment and those who have not. Eligible participants are women 18–50 with regular 24–35 day cycles who meet medication and health criteria.

Why it matters

Potential benefit: If validated, these biomarkers could enable a blood test to identify hormone sensitivity and help guide diagnosis and treatment choices for PMDD.

How similar studies have gone: The investigators previously reported an epigenetic biomarker that predicted postpartum depression with over 80% accuracy and a small cross-sectional PMDD cohort showed the biomarker distinguished cases from controls in the luteal phase.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* female sex
* regular menstrual cycles (24-35 days)
* age 18-50 years
* ability to give written informed consent

Exclusion Criteria:

* psychiatric medication use in the past 2 months;
* substance use disorder in the past 2 months (per MINI);
* lifetime history of psychotic disorder including schizophrenia, schizoaffective disorder, major depression with psychotic features (per MINI);
* history of psychiatric disorder other than PMDD in past year (per MINI);
* active suicidal ideation with plan or attempt in past 6 months (per MINI);
* steroid hormone or hormonal contraceptive use (except levonorgestrel as emergency contraceptive) in past 2 months;
* pregnancy in past 6 months;
* history of brain injury;
* current or history of endocrine disorder including uncontrolled diabetes or thyroid disease;
* BMI\>40.

Where it's running

  • Johns Hopkins Reproductive Mental Health Center
    Baltimore, Maryland, United States
    Recruiting

Study contacts

  • Principal investigator: Liisa Hantsoo, Ph.D. — Johns Hopkins University
  • Study coordinator: Victoria Seo, B.S.
  • Email: vseo1@jh.edu
  • Phone: 302-464-8320‬

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.